Active Immunization, the cornerstone of modern medicine, epitomizes humanity's triumph over infectious diseases. Through the administration of vaccines, the body's immune system is stimulated to recognize and combat specific pathogens, thereby building a robust defense against future encounters. This proactive approach not only shields individuals but also contributes to community-wide immunity, known as herd immunity, which protects those who cannot be vaccinated. Vaccines come in various forms, from live attenuated viruses to inactivated pathogens, as well as subunit vaccines, recombinant vaccines, and mRNA vaccines, each tailored to provoke a targeted immune response. They are meticulously developed and rigorously tested to ensure safety and efficacy, undergoing phases of clinical trials before regulatory approval.
The impact of vaccines on public health cannot be overstated. Diseases like smallpox and polio, once rampant, have been virtually eradicated through widespread vaccination campaigns. Vaccines have prevented countless deaths and disabilities, enabling children to thrive and communities to flourish. In recent times, vaccines have played a pivotal role in combating emerging infectious threats, such as influenza, measles, and COVID-19. They are instrumental in curbing outbreaks, protecting vulnerable populations, and restoring societal stability.
However, vaccine hesitancy and misinformation pose significant challenges to global immunization efforts. Addressing these concerns requires robust education, transparent communication, and equitable access to vaccines for all communities.
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India